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Abstract (word count: 239): 
Murine syngeneic tumor models are critical to novel immuno-based therapy development but 
the molecular and immunological features of these models are still not clearly defined. The 
translational relevance of differences between the models is not fully understood, impeding 
appropriate preclinical model selection for target validation, and ultimately hindering drug 
development. Across a panel of commonly-used murine syngeneic tumor models, we showed 
variable responsiveness to immunotherapies. We employed array comparative genomic 
hybridization, whole-exome sequencing, exon microarray analysis, and flow cytometry to 
extensively characterize these models, which revealed striking differences that may underlie 
these contrasting response profiles. We identified strong differential gene expression in 
immune-related pathways and changes in immune cell-specific genes that suggested 
differences in tumor immune infiltrates between models. Further investigation using flow 
cytometry showed differences in both the composition and magnitude of the tumor immune 
LQILOWUDWHVLGHQWLI\LQJPRGHOVWKDWKDUERUµLQIODPHG¶DQGµQRQ-LQIODPHG¶WXPRULPPXQH
infiltrate phenotypes. We also found that immunosuppressive cell types predominated in 
syngeneic mouse tumor models that did not respond to immune-checkpoint blockade, 
whereas cytotoxic effector immune cells were enriched in responsive models. A cytotoxic 
cell±rich tumor immune infiltrate has been correlated with increased efficacy of 
immunotherapies in the clinic and these differences could underlie the varying response 
profiles to immunotherapy between the syngeneic models. This characterization highlighted 
the importance of extensive profiling and will enable investigators to select appropriate 
models to interrogate the activity of immunotherapies as well as combinations with targeted 
therapies in vivo.  
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Introduction 
Recent clinical successes treating tumors with immunotherapies, including approval of the 
immune-checkpoint blockade antibodies ipilimumab (anti±CTLA-4) and nivolumab and 
pembrolizumab (anti±PD-1), demonstrate the potential to transform treatment paradigms and 
improve patient outcomes (1-3). These treatments represent a shift in the approach to cancer 
therapy as they do not target the tumor cells but instead target the immune system to 
circumvent inhibitory pathways that attenuate effective antitumor immune responses. Despite 
these successes, responses to immunotherapy usually remain restricted to a subpopulation of 
patients (4, 5). In order to broaden the cancer patient population benefiting from 
immunotherapy, a greater understanding is needed of the factors that impact response and the 
potential for combination of different therapies. It is clear that T-cell infiltration varies greatly 
between individual tumors, patients and disease types, with some considered to harbor more 
LPPXQRJHQLFHJµhot¶µinflamed¶) tumors (6, 7), characterized by greater T-cell infiltration 
and Th1 cytokine expression, and overlapping drivers of immunosuppression. In contrast, 
other tumors may be characterized by a sparse T-cell infiltrate (i.e., immunologically µFROG¶, 
potentially as a consequence of reduced immunogenicity. The phenotype of the tumor 
immune infiltrate correlates with both patient prognosis (8) and outcome following 
immunotherapy (9). Intrinsic tumor characteristics such as neoantigen load can also affect 
response to immunotherapy (10, 11), possibly by modulating tumor immunogenicity (12). 
Human xenograft tumor models, in which human tumor cell lines are implanted in mice, have 
played a critical role in understanding traditional cytotoxic or targeted cancer therapies. 
However, in the context of immunotherapy, these routinely used and well characterized 
models are not suitable, since they lack an intact immune system. Several immunocompetent 
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mouse model systems can be used to study immunotherapies but each brings with it a series 
of challenges and limitations (reviewed in (13, 14)). For example, genetically engineered 
mouse models (GEMMs) recapitulate the anatomical location and encompass some disease-
specific mutations frequently observed in human cancer, but they require large colonies of 
mice, have extended latency periods and, in contrast to the clinical setting, often display 
limited mutational burden and minimal genetic mosaicism (15). Alternatively, models based 
on subcutaneous or orthotopic implantation of syngeneic tumor cell lines have short latency 
periods, are reproducible and high-throughput; on the basis of this they have been the 
workhorse of cancer immunology for several decades (13). These tumor models have been 
invaluable in providing preclinical proof of concept for candidate immunotherapeutic drugs 
(16, 17), as well as building an understanding of mechanism of action and evaluating 
potential biomarkers of response (18, 19). However, to date, the majority of studies have been 
performed in a small number of models (compared to xenografts (14)) and, despite their 
widespread use, surprisingly little is known about the genotypes and phenotypes of these 
syngeneic murine tumor models (14). Ultimately, a better understanding of these models is 
required to enable appropriate model selection and to permit both data interpretation and 
extrapolation to the clinic (13, 14).    
Here, we describe a comprehensive characterization of the genomic, transcriptomic, and 
immunological composition of several murine syngeneic tumor models. Using flow 
cytometry, we characterized the tumor immune infiltrate, the spleen and tumor-draining 
lymph nodes (TDLN) in a panel of our most frequently-used models. This enabled us to 
examine whether the genotype and gene expression profile of the tumor cells associated with 
their immunophenotype in vivo, and determine how this related to response following 
immune-checkpoint blockade. This study highlights the need for extensive characterization of 
models used for preclinical immunotherapy research, and provides data that will, based on 
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the proposed mechanism of action of the therapy being evaluated, support investigators in 
selecting appropriate models using hypothesis-driven rationales. It also forms the basis of a 
dataset that will increase the translational relevance of studies, by allowing parallels to be 
drawn between models and human disease phenotypes. Moreover, these data can be readily 
applied to expedite the discovery and development of novel immunotherapies by increasing 
the efficiency of preclinical drug development. 
 
Materials and Methods  
Tumor models. An overview of the experiments performed is shown in Supplementary Fig. 
S1. All in vivo experiments were performed in accordance with the UK Animal (Scientific 
Procedures) Act 1986 and the EU Directive 86/609, under a UK Home Office Project License 
and approved by the Babraham Institute Animal Welfare and Ethical Review Body, using 
guidelines outlined by Workman et al. (20). C57BL/6 and BALB/c mice were supplied by 
Charles River UK at 8±10 weeks of age and > 1 8g and housed under specific pathogen-free 
conditions in Tecniplast Green Line IVC Sealsafe cages holding a maximum of 6 animals 
with irradiated aspen chip bedding, Nestlets nesting material, a cardboard tunnel and wooden 
chew blocks. Mice were housed on a 12/12 light/dark cycle, with ad libitum UV-treated water 
and RM1 rodent diet.   
100 µL of cells in PBS were subcutaneously injected into the left flanks of mice (unless 
otherwise stated; details of the cell lines and cell numbers are in Supplementary Table S1). 
Cells did not undergo any in vivo passaging (except for the B16F10 AP-3 cell line) and were 
maintained under limited passage from original stocks (typically under 5). We did not 
undertake additional independent validation. Tumor volume was measured using the formula 
(width2 × length)/2 and tumors were collected when reaching an average of 150 mm3. For the 
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Pan02 cell line, 50 µL of cells in ice-cold matrigel (Corning) were surgically implanted into 
the pancreas tail. For tumor growth studies, mice were injected intraperitoneally with 10 
mg/kg of either anti±CTLA-4 (mouse IgG2b, clone 9D9, Biolegend) or anti±PD-L1 (rat 
IgG2b, clone 10F.9G2, BioXCell) or the respective isotype controls (ĮNIP, MedImmune). 
Array comparative genomic hybridization (aCGH). Microarray services were provided by 
Almac Diagnostics, UK. Genomic DNA was extracted from one sample of each mouse tumor 
cell line using the DNeasy Blood and Tissue Kit (Qiagen) and quality controlled (OD 
A260/230 ratio using a 2100 Bioanalyzer (Agilent). Samples were 2-color labelled 
using the genomic DNA labelling kit PLUS (Agilent), hybridized on Agilent Mouse genome 
CGH 1x224K oligo microarrays using the Oligo aCGH Hybridization kit (Agilent) and 
scanned on an Agilent Microarray scanner. Reference mouse genomic DNA (Merck) was 
used as a control. All microarray data are deposited into GEO (accession numbers 
GSE85509). After normalization to the control mouse genome, probe log2 ratios for 
autosomal genes were converted to copy number variation (CNV) values (Supplementary 
Table S2 and Supplementary Dataset). 
Whole-exome sequencing (WES). DNA was extracted from cell lines using the DNeasy 
Blood and Tissue kit (Qiagen). DNA samples were evaluated using an E-Gel (Invitrogen) and 
PicoGreen fluorometry to measure quality and quantity, respectively. DNA samples were 
then physically sheared to the desired size using a Covaris E220 Focused-ultrasonicator. 
Library preparation and enrichment were carried out using an Agilent SureSelectXT Mouse 
All Exon 49.6Mb design, followed by sequencing on an Illumina HiSeq 2000. Basecall files 
(*.bcl) were de-multiplexed and converted to fastq.gz format using CASAVA v1.8.2 
(Illumina). CrossMap (21) was used to lift the BED files over to mm10 reference for variant 
calling.  The reads were aligned using BWA (22) and variants were called using FreeBayes 
(23) and VarDict (24).  Copy number was inferred from the exome data using Seq2C and 
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CNVKit (25) for approximately 1500 immune system and oncology-related genes.  Variants 
were strain-specifically annotated using data downloaded from ftp://ftp-
mouse.sanger.ac.uk/REL-1505-SNPs_Indels/strain_specific_vcfs/ for C57BL_6NJ, 
BALB_cJ, and DBA_1J. Sequencing data were deposited in the European Nucleotide 
Archive (accession PRJEB12925).  
Targeted sequencing. DNA was isolated from fresh-frozen tumor tissue utilizing the Qiagen 
MagAttract kit and concentrations determined by Nanodrop spectrophotometry. Focused 
amplicon sequencing of 64 genes commonly mutated in cancer patients (based on proprietary 
datasets and the COSMIC database (26)) was carried out utilizing a custom AmpliSeq panel 
(Life Technologies) to confirm their mutation status. Two pools of amplicons were generated 
DQGQJRI'1$ZDVXWLOL]HGIRUHDFKSRRO7KHPDQXIDFWXUHU¶VSURWRFROZDVIROORZHGIRU
target amplification, adapter ligation and purification. Libraries were sequenced on an Ion 
PGM instrument utilizing the 318 chip. Reads were aligned with Bowtie v2.0 (27) using the 
mouse reference version mm10 (B6 strain). Single nucleotide variants were called using 
VarScan v2.3.2 (28) with minimum average quality=30, minimum variant allele read 
FRXQW DQG)LVKHU¶VH[DFWW-test p<0.01. Minimum variant allele frequencies of 7% were 
called with a minimum of 200X total depth at the locus. Annotation was conducted using 
Annovar (29). 
Transcriptomics. Microarray services were provided by Almac Diagnostics, UK. RNA was 
extracted from the tumor, spleen and lymph node (LN) tissues from each model using 
RNAStat 60 (Amsbio) and quality of total RNA was determined using a 2100 Bioanalyzer 
(Agilent). After amplification using the WT-Ovation Pico amplification kit (NuGEN 
Technologies), cDNA was generated using WT-Ovation Exon module. After quality testing, 
cDNA was fragmented, labelled and hybridized using the FL-Ovation cDNA Biotin Module 
V2 (NuGEN Technologies) to Mouse Exon 1.0 ST arrays (Affymetrix). All microarray data 
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are deposited into GEO (accession numbers GSE85509). Microarray data underwent Robust 
Multichip Algorithm pre-processing and normalization in Omicsoft ArrayStudio. 1192934 
exon probes remained with a probe detection p value <= 0.05. Quality control excluded 2 
outliers. Log2 transcript expression values were determined as the median of detected core 
probes.  
To enable cross-comparison of tumor samples between models, five simulated pooled 
samples (SPS) were generated by proportional resampling with replacement of the log2 
expression intensities for each gene (R and Omicsoft ArrayStudio). The SPS tumor control 
group was compared to tumor samples from each model to identify differentially-expressed 
genes (DEGs) using empirical Bayesian analysis (including vertical (within a given 
comparison) p-value adjustment for multiple testing) (Fios Genomics). LN and spleen 
samples were compared with their tissue, strain and sex-matched controls. DEGs were 
selected using both FDR Adjusted p-YDOXH%HQMDPLQLDQG+RFKEHUJPHWKRGDQGIROG
FKDQJHRU-2.0. 
DEGs underwent functional enrichment and network analyses using Ingenuity Pathway 
Analysis (IPA, Ingenuity® Systems). Enrichment analysis results were cross-compared using 
the IPA comparison tool. The differentially-regulated non-disease canonical pathways with 
the top ten highest and lowest activation Z scores per model were ranked by summed 
absolute Z score for all 15 models and plotted in a heatmap. Normalized log2 gene expression 
intensity per tumor sample for 96 cell type-annotated genes from the Nanostring nCounter® 
PanCancer Immune Profiling Panel gene-list underwent hierarchical cluster analysis (HCA) 
(normalized, linkage = Ward and distance = Euclidean) to cluster samples only, with genes 
ordered by immune cell type annotation (Matlab). 
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Flow cytometry. Tumors were disaggregated using the GentleMACS Mouse Tumor 
Dissociation kit (Miltenyi Biotech). Spleens and TDLNs were dissociated through a 70 µm 
nylon cell strainer. Spleens were resuspended in red blood cell lysis buffer (Sigma) for 1 
minute. All cells were then stained with a viability dye (ThermoFisher) and blocked with 
antibodies to CD16/CD32 (eBioscience) before staining with fluorescence-conjugated 
antibodies (Supplementary Table S4) in flow cytometry staining buffer with Brilliant Stain 
Buffer (BD Biosciences). Intracellular staining was performed using the FoxP3/transcription 
factor staining buffer set (eBioscience) and cells were fixed in 3.7 % formaldehyde/PBS. 
Counting beads (123Count eBeads, eBioscience) were added to the samples before 
acquisition on an LSRFortessa (BD Biosciences) and analysis using FlowJo (Tree Star). 
Gating strategies are shown in Supplementary Fig. S2. To enable comparisons between 
tumors, cell counts were normalized by dividing the cell count obtained using the counting 
beads by the tumor volume. 
Cytokine quantification. Tumors were snap-frozen in liquid nitrogen then lysed on a 
TissueLyser II (Qiagen) in 1% Triton-X/PBS with phosphatase inhibitors (PhosSTOP, 
Roche), protease inhibitors (cOmplete, Roche) and tungsten carbide beads (Qiagen). Lysates 
were freeze-thawed, centrifuged and diluted to 0.5mg/mL before analysis of 10 cytokines 
using the mouse Proinflammatory Panel 1 V-PLEX immunoassay (Meso Scale Discovery). 
Data was log transformed and plotted using Matlab. 
Statistical analyses. Flow cytometry data was analyzed in GraphPad Prism using One-Way 
ANOVA with 7XNH\¶Vcorrection for multiple comparisons. For tumor growth studies, group 
sizes were determined using power analyses based on the variability of the models in pilot 
studies. Tumor growth data were log10 transformed and the effectiveness of the therapy (Tr) 
with respect to the baseline treatment performance was assessed with a linear mixed-effect 
model (30, 31). The Yij, representing log10-transformed ith tumor volume observed at jth 
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assessment point (T), follows the linear growth model: Yij = a0i + a1i * Tj + eij, where a0i 
DQGDLGHQRWHLQGLYLGXDOLQWHUFHSWDQGVORSHSDUDPHWHUVUHVSHFWLYHO\DQGHLMa1ı
represents model error. Both intercept and slope are assumed to express random effects: 
a0i = g00 + g01*Tri + u0i, a1i = g10 + g11*Tri + u1i, with u0i a1ıDQGXLa1ı
7KHSDUDPHWHUVJJDQGJJUHSUHVHQWWKHSDUDPHWHU¶VIL[HG-HIIHFWVıDQGıı
correspond to intra- and inter-tumor variance, respectively. Models were defined as 
µUHVSRQVLYH¶LIWKHJURZWKNLQHWLFVRIWKHWUHDted group compared to the control group was 
significantly different (P < 0.05).  
 
Results  
Model-dependent differences in anti-tumor response to anti±CTLA-4 and anti±PD-L1. 
During our preclinical investigation of CTLA-4 and PD-L1 as targets for immune-checkpoint 
blockade, we tested the antitumor activity of surrogate antibodies in several murine syngeneic 
tumor models (32). Significant tumor growth inhibition was seen following anti±CTLA-4 
treatment in the CT26 (P  0.0001) and RENCA (P  0.0001) models (Fig. 1A), whereas PD-
L1 demonstrated activity only in the CT26 model (P  0.0001) (Fig. 1B). This highlighted a 
need to better understand the underlying immuno-biology of murine syngeneic tumor models 
in order to identify potential drivers of response and enable rational selection of appropriate 
models for preclinical activity testing.  
 
Genomic analysis reveals a high degree of diversity in copy number variations. We 
performed genome-wide aCGH analysis on 16 in vitro murine tumor cell lines to gain an 
understanding of broad amplification and deletion events. CNV levels were not affected by 
12 
 
the method of tumor cell line generation since CNV frequency of carcinogen-induced CT26, 
genetically-induced TRAMP-C2 and spontaneous LL/2 cell lines were not markedly 
dissimilar (5.74%, 5.75% and 5.04% respectively) (Fig. 2). No difference in the overall 
burden of genomic aberrations was seen in the CT26 cell line compared to the others (5.74% 
of genes studied had CNV in CT26 vs. a mean of 6.05% across the other 15 cell lines). In 
order to assess CNVs against a paired background strain as opposed to a reference genome, 
we also investigated somatic gene copy number using whole-exome sequencing (Fig. 3A-D). 
Gain of a single gene copy was frequent (>5% of genes studied) in the RENCA and P815 
lines, but amplifications of more than one extra copy much less so. We observed few 
deletions in the cell lines, although the most common feature across the models was the 
heterozygous or homozygous deletion of the Cdkn2a tumor suppressor gene (found in 9 of 11 
cell lines) (Fig. 3B).  
 
Comparing mutational status permits model selection for tumor-targeted therapies. We 
also characterized the somatic mutational status of these genes using WES on a subset of the 
murine in vitro cell lines and further investigated 64 prominent cancer genes using targeted 
deep sequencing (Supplementary Table S3 and Supplementary Fig. S3). Our analysis 
revealed that several tumor cell lines did not carry mutations prevalent in the matched clinical 
disease. For example, Pan02 is often used as a pancreatic cancer model but lacked mutations 
in the Kras gene, which are observed in >90% of human pancreatic cancers (33) so it may 
only be a relevant model for a rare subtype of the disease. CT26 cells harbored mutations in 
the Apc and Kras genes, which are frequently observed in human colorectal cancer (34), but 
lacked the frequent mutation in Trp53. In contrast, LL/2 had many of the major mutations 
found in lung cancer, such as Trp53 and a Cdkn2a deletion (35). The B16 lines bore a 
mutation in the Braf gene, as is frequently observed in human melanoma (36), however this 
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mutation was not analogous to the V600E mutation that underlies sensitivity to BRAF 
inhibitors (37). Comparison of the mutational profile of the murine tumor cell lines with 
frequently-mutated genes found in the cancer type from the same tissue of origin revealed 
that, although the cell lines carried at least one recurrent mutation seen in the corresponding 
cancer type, 4 out of 9 models analyzed lacked mutations in the gene most frequently mutated 
in the corresponding human cancer type (Supplementary Fig. S4). The mutational status of 
immune-relevant genes was also evaluated across the cell lines to investigate whether cell-
intrinsic genetic changes were present that could affect the ability of cell lines to recruit an 
immune response (Fig. 3D). We found that the most prevalent aberrations affected the 
complement system, including 6 of the top 50 most mutated or amplified genes in the dataset. 
Tumor-derived complement has been previously shown to both promote tumor growth but 
also contribute to the immune surveillance of tumors (reviewed in (38)) and even impact the 
tumor immune infiltrate by affecting the number of infiltrating CD8+ T-cells and myeloid 
cells, although these immunomodulatory effects are very context-dependent (39, 40). Several 
other genes with aberrations in the cell lines have also been shown to affect tumor growth 
such as fibronectin (Fn1) (41), Cd40 (42) or Nfatc3 (43). This analysis also revealed that 
CT26 and MC38 (both derived from carcinogen-induced colorectal tumors) had the highest 
somatic nonsynonymous mutational burden, with 2955 and 3018 mutations respectively (Fig. 
3E). ID8, derived from a spontaneous tumor, had the lowest mutational burden (102 
mutations), followed by TRAMP-C2, derived from a tumor in a genetically-engineered 
mouse (104 mutations). Thus, mutational burden appeared to be associated with the method 
of cell line generation in this panel, with cell lines derived from carcinogen-induced tumors 
having on average a higher mutational burden (1827 mutations) than spontaneous (1220 
mutations) or GEMM-derived tumors (104 mutations).  
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Given that clonal selection and evolution can take place during in vivo tumor development, 
we performed whole-exome sequencing of CT26 cells grown in vitro and in vivo (Fig. 3F and 
G). In the tumor, we detected 2580 out of 2955 (87.3%) somatic mutations found in the cell 
line. A high correlation (r = 0.766) was observed between the mutant allele frequency in vitro 
vs. in vivo (Fig. 3F). Disparities in these data may be due to the use of an unfractionated 
tumor preparation for this analysis. There were genomic alterations in 57 cancer and immune-
relevant genes found in the CT26 cell line which were not detected in the tumor, but these 
were mostly copy number gains that are more difficult to accurately quantify in 
heterogeneous in vivo samples (Fig. 3G). There were only four somatic mutations detected in 
the tumor which were not in the cell line (Erbb3, Ikbkb, Mnx1 and Notch2). These could have 
arisen due to selective pressures at play in the tumor microenvironment.  
 
Transcriptomic comparison reveals striking immunological heterogeneity. To investigate 
the baseline characteristics of the syngeneic tumor models that could underlie their 
differential responsiveness to immune-checkpoint blockade, we analyzed the transcriptomes 
of untreated established in vivo tumors. Pathway enrichment of differentially-expressed genes 
in tumors revealed activation of multiple immune pathways with a high degree of 
heterogeneity across the models. These included innate immune±related pathways, such as 
pattern recognition receptors, IL8, TREM1, phagocytosis, and IL6 signaling (Fig. 4A). These 
pathways revealed reduced activation in tumors from B16 cell lines compared to other 
models. However, a limited number of pathways (PPAR, RXR, LXR, and PTEN) were more 
highly activated in the B16 tumors compared to the other models. These data supported the 
hypothesis that tumors from B16 cell lines DUHPRUHLPPXQRORJLFDOO\µVLOHQW¶compared to 
other tumor types, potentially underlying their reduced responsiveness to immune-checkpoint 
blockade. Hierarchical cluster analysis (HCA) revealed that the pathway activation profile in 
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CT26 tumors was not substantially different from those of other tumor types, suggesting that 
transcriptomic differences do not completely define response to immune-checkpoint 
inhibitors (Fig. 4A). We also specifically investigated the expression of MHC class I and II 
pathway genes in the tumors and found that the B16 tumors, TC1 and LL/2 had less 
expression of these genes compared to the other models. The TRAMP tumors had low 
expression of MHC class I pathway genes, whereas the MC38 tumors had low expression of 
MHC class II pathway genes (Fig. 4B). 
To determine whether differences in the tumor immune infiltrate could be affecting 
responsiveness to immune-checkpoint blockade, we investigated the expression of immune 
cell type±specific genes. Unsupervised HCA revealed clustering by tumor model and clear 
changes in expression, suggesting variation in tumor immune infiltrates across the models 
(Fig. 5). Several findings supported the validity of this approach, such as the elevated 
expression of a subset of mast cell-specific genes including Kit (20 fold increase compared to 
the SPS tumor control group), Ctsg (22 fold increase) and Cma1 (2.5 fold increase), which 
occurred only in the P815 mastocytoma tumors where these genes are expected to be 
expressed in the tumor cells, as well as potentially in the immune infiltrate. B16 tumors again 
appeared LPPXQRORJLFDOO\µVLOHQW¶ZLWKORZH[SUHVVLRQRIimmune cell type-specific genes, 
apart from some NK cell±specific genes. Elevated gene expression was observed for 
cytotoxic cell-specific genes Gzma (5.2 fold increase) and Klrd1 (1.8 fold increase) in the 
CT26 tumors, potentially linking effector function of tumor-infiltrating immune cells and 
responsiveness to immune-checkpoint inhibitors. 
 
Flow cytometric immune profiling reveals heterogeneity in tumor immune infiltrates 
across models. Given the diversity in the expression of immune-related genes, we further 
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profiled the tumor immune infiltrate across both our immune-checkpoint blockade responsive 
and nonresponsive models by flow cytometry. Tumors were collected at an average volume 
of 150 mm3, as this often corresponds to the tumor volume at initiation of dosing in activity 
studies. The immune infiltrate was profiled by staining for 9 non-overlapping innate and 
adaptive cell phenotypes and their frequency determined both as a proportion of the CD45+ 
cells and as absolute cell count per mm3 of tumor. Immune cell numbers per mm3 of tumor 
revealed striking variations across models (Fig. 6A and B). B16F10 AP-3 tumors contained 
the smallest immune infiltrate with roughly 800 CD45+ cells per mm3 whereas LL/2 tumors 
had the largest infiltrate with 5500 CD45+ cells per mm3 (P < 0.0001). Moreover, the relative 
proportions of immune cell types also differed profoundly. For example, 4T1 tumors 
predominantly contained granulocytic myeloid-derived suppressor cells (gMDSCs, > 40% of 
their immune infiltrate), whereas LL/2 and MC38 tumors contained mainly monocytic 
MDSCs (mMDSCs, 33% and 47%, respectively). Notably, CT26 tumors contained the 
highest number of NK-cells (520 per mm3) and an increased proportion of granzyme B+ NK 
cells compared to other models (Fig. 6C). Additionally, the CT26 and RENCA models 
contained the highest proportions of T cells. Within the CD8+ T-cell population, the 
proportion of reinvigorated cells (expressing markers of T-cell exhaustion (PD-1 and Eomes) 
but having undergone a reversal of this exhaustion leading to upregulation of Ki67 and 
granzyme B) (44) was highest in CT26 tumors (Fig. 6D). The absolute cell counts revealed 
that CT26, and to a lesser extent RENCA, tumor immune infiltrates were rich in cytotoxic 
immune cells whereas 4T1, B16F10 AP-3, LL/2 and MC38 are predominantly composed of 
cell types considered to be immunosuppressive. 
In tumor lysates, the highest expression of several pro-inflammatory cytokines such as IL2, 
IFNȖTNFĮ and ILȕ were found in the CT26, MC38, and RENCA models (Fig. 6E). In 
contrast, higher levels of Th2-associated cytokines such as IL4 and IL10 were found in the 
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MC38, 4T1 and B16F10 AP-3 models. Notably, KC/GRO, a chemoattractant for neutrophils 
and MDSCs, was elevated in the MDSC-rich 4T1, MC38 and LL/2 tumors. 
To expand our observations, we also assessed spleens and tumor-draining lymph nodes from 
these animals (tissues from non-tumor bearing mice were included to highlight changes from 
baseline). An > 8-fold increase in splenic gMDSCs/neutrophils was observed in 4T1 tumor-
bearing mice compared to tumor-naïve mice (P = 0.0028) (Fig. 7A), mirroring the 
predominance of these cells in the tumor (Fig. 7E). A common finding was that spleens from 
tumor-bearing mice had smaller percentages of T-cells (30%) relative to tumor-naïve controls 
(42%) (P < 0.0001) (Fig. 7A and B). In tumor-naïve animals, a comparison of both genetic 
strains showed that BALB/c LNs had a larger proportion of CD4+ T-cells compared to 
C57BL/6 LNs (49.7% vs. 32.3% P < 0.0001), which had more B cells (13.9% vs. 23.6% P = 
0.0003) (Fig. 7C and D). In TDLNs, an expansion of B cells was seen vs. control tumor-naïve 
LNs (P = 0.0003) and this was most marked in the LL/2 and MC38 models, where it was 
accompanied by a corresponding decrease in the proportions of T cells and NK cells. Despite 
the striking contrasts in the composition of the tumor immune infiltrate (Fig. 7E and F), this 
was not mirrored in the TDLNs. 
 
Discussion: 
Murine syngeneic tumor models play a central role in the advancement of novel 
immunotherapies, however, there is a need to fully elucidate their distinct molecular and 
immunological characteristics. In the present study we provide a resource to rationalize the 
selection of syngeneic models to test specific hypotheses; increasing the value of such studies 
and reducing the numbers of animals used in scientific research. In addition to characterizing 
the tumor microenvironment, we provide a molecular annotation of these models to describe 
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the specific driver mutations that can be leveraged to guide immunotherapy combinations 
with molecularly-targeted therapies. Indeed, such combinations hold considerable promise to 
broaden the patient population benefiting from immunotherapy.  
We have identified models in which the dominant immunological phenotype of the tumor is 
associated with myeloid immunosuppression, e.g., increased gMDSC and mMDSC 
infiltration in the 4T1, MC38, and LL/2 models. We have also identified models, particularly 
the B16F10 AP-3, that are poorly infiltrated by immune cells. In contrast, other models are 
both rich in tumor immune cell infiltration but also harbor more balanced populations of 
effector and suppressive immune cell populations, e.g., CT26 and RENCA. This 
immunological diversity broadly recapitulates the diversity of tumors observed clinically and 
therefore provides a powerful resource to evaluate different immunotherapies in the context 
of these distinct microenvironments. An example of this could be the selection of an 
LPPXQRORJLFDOO\µFROG¶WXPRUPRGHOVXFKDV%)-AP3 to evaluate the capacity of 
treatment to transform the tumor microenvironment leading to enhanced immune priming and 
immune cell infiltration into tumors, e.g., with radiotherapy, agonism of pattern-recognition 
receptors, or through vaccine approaches. Likewise, modelling RILPPXQRORJLFDOO\µKRW¶
tumors is also translationally relevant and the CT26 or RENCA models may provide suitable 
settings to evaluate experimental therapeutics.   
Our analysis of the somatic mutation profile of the murine cell lines reveals genetic 
disparities when compared to the prevalent mutations in the analogous clinical disease. 
Examples of these include Trp53 in CT26 or Kras in PAN02. However, many of the genes 
that are commonly mutated in the clinical setting are also mutated across the preclinical 
models tested, offering opportunities to understand the impact of these mutations in a 
syngeneic setting. In particular these data will enable researchers to identify models with both 
the relevant pathway addiction for a defined molecular target, e.g., MEK, BRAF (45), and 
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overlay this with a characterized microenvironment to permit pertinent and appropriate 
combinations of immunotherapy and small molecule inhibitors to be evaluated.  
Our study also highlights differences between the activity of immunotherapies in a preclinical 
setting and clinical activity in the analogous human cancer type. An example of this is the 
contrast between the strong preclinical responses to anti±CTLA-4 and anti±PD-L1 treatment 
in the CT26 model, derived from a murine colorectal tumor, and clinical responses in 
colorectal cancer in which, with the exception of patients with mismatch repair-deficient 
disease, limited activity with immune-checkpoint blockade has been observed to date (46). 
Poor responses to treatment with either anti±PD-L1 or anti±CTLA-4 were observed in the 
B16 model, derived from a murine melanoma, which contrasts with the encouraging 
responses reported for melanoma in the clinic (47). However, when these responses are 
assessed in the context of the distinct tumor microenvironments observed across the 
preclinical models, our results are broadly in agreement with clinical findings, which 
demonstrate an association between CD8+ T-cell infiltration into the tumor and outcome 
following immune-checkpoint blockade (9, 48, 49). Indeed, our work also revealed that 
tumors such as CT26, in which the immune infiltrate contains greater numbers of cytotoxic 
immune cells such as CD8+ T cells and NK cells, were more responsive to immune-
checkpoint blockade than those with comparatively little immune or predominantly 
immunosuppressive infiltrate. Thus, we conclude that the power of the models lies in 
recapitulating both a distinct phenotype of tumor microenvironment and mutation profile, 
rather than directly relating to the analogous human disease setting. 
An interesting observation was that although the composition of the tumor microenvironment 
across the syngeneic models tested was strikingly varied, this contrasted starkly with the 
relative homogeneity in the immune phenotype observed in secondary lymphoid organs such 
as the tumor-draining lymph nodes and spleens. This homogeneity was also reflected by gene 
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expression, with markedly fewer differentially-expressed gene pathways observed in these 
tissues when compared to those in the tumors (Supplementary Fig. S5). Overall, these data 
suggest that the greatest differences between models may result from the preferential 
chemoattraction, retention, and or differentiation of immune cells within the tumor 
microenvironment rather than from skewing of the systemic immune response, and therefore 
the likely factors that are driving response reside within the tumor rather than within the 
peripheral immune compartments. Again, this finding is also in keeping with the majority of 
data from the clinic to-date, where the most promising predictive biomarkers have been found 
in tumor tissue, rather than in peripheral blood (49). 
Several of our findings are concordant with previous observations, such as the predominant 
loss of Cdkn2a among the cell lines, which has been described to result from cell culture 
selective pressures (50) and is also prevalent across multiple human cancer types (51). 
Previous studies have also shown that different syngeneic tumor models can respond 
differently to treatment (16, 49, 52). It has been hypothesized that these differences could be 
due to variability in immunogenicity of the models (13) but, until now, the similarities and 
differences between these models have not been comprehensively characterized. The most 
extensive study, to our knowledge, included 6 commonly-used syngeneic models with 
analysis limited to the expression of 27 immune-related genes and staining for 4-6 immune 
cell types by immunohistochemistry and flow cytometry (52). We also saw a high level of 
agreement in somatic mutation results with previous genetic characterization of the CT26 cell 
line, with >60% of mutated genes matching those in the study by Castle et al. (53, 54). 
Although another study described fewer somatic mutations in CT26 and 4T1, 80-90% of 
those mutated genes matched our results (54) and the relative proportions of somatic 
mutations was conserved, with >10 fold more mutations in CT26 compared to the 4T1. 
Likewise, comparison of our somatic mutation results in the ATCC B16F10 line to those in 
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Castle et al. (55) showed over 90% concordance in the mutated genes found in both studies 
including Brca2, Trp53, Jak3, Atm, Pten and Mdm1. Disparities in somatic mutations 
between studies could be due to differences in cut-off levels, sensitivity and methodology, as 
well as cell line divergence. Our profiling of CNV, using both aCGH and WES analysis 
paired with the BALB/c mouse background, did not show the same large regions of triploidy 
and tetraploidy in CT26 seen by Castle et al. (53). However, for such multichromosomal 
regions it is unlikely that this would be due to divergence in the CT26 cell lines, but rather 
due to methodological differences such as stringency of CNV calling.  
In conclusion, we provide extensive characterization of a range of commonly used murine 
syngeneic models to rationalize model selection based on the biology of the tumor cell and 
the tumor microenvironment. Moreover, a greater understanding of model biology allows 
more robust alignment between response, mechanism of action, and the biology of human 
cancer subtypes that may ultimately improve the efficiency of drug discovery. 
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Figure legends: 
Figure 1: The antitumor activity of anti±CTLA-4 and anti±PD-L1 treatment varies 
across a range of syngeneic models  
Tumor growth curves for 6 subcutaneous murine syngeneic tumor models treated with either 
(A) CTLA-4 antibody clone 9D9 (10 mg/kg) or (B) PD-L1 antibody clone 10F.9G2 (10 
mg/kg). Treatment was given by intraperitoneal injection on the days marked with ticks on 
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the x axis of the graphs. n PLFHSHUJURXSP < 0.0001, ns: non-significant P  0.05, 
linear mixed effect model test. Data is representative of at least 2 independent experiments. 
 
Figure 2: Copy number variations strongly differ between the cell lines  
CNVs for 16 cell lines determined using aCGH analysis. Genomic regions are sorted by 
chromosome, and copy number changes of roughly 10 genes displayed, with DPSOLILFDWLRQV 
5 copies as light red lines, amplifications > 5 copies as dark red lines, loss of one copy as 
light blue lines and deletions of both copies as dark blue lines.  
 
Figure 3: Profiling of somatic mutations reveals heterogeneity across syngeneic models 
Profiling by aCGH, whole-exome and targeted sequencing across 11 cell lines showing (A) the 
percentage of altered genes from 332 cancer-associated genes (selected from the COSMIC 
database where both copy number and mutational status data was available), (B) the top 50 
most altered cancer-associated genes, (C) the percentage of altered genes from 252 immune-
related genes (from the Nanostring nCounter® Mouse Immunology panel gene list, excluding 
those already present in the cancer-associated gene list, and where both copy number and 
mutational status data was available), and (D) the top 50 most altered immune-related genes. 
Somatic mutations and CNVs are marked for each gene with the percentage of samples 
altered along the side of the heatmap. Sideway bargraphs show the total number of genomic 
alterations across samples, with genes ordered genes from most to least altered. Human 
homolog genes are stated in brackets beside the mouse gene names where these differ. (E) 
Number and type of somatic mutations in protein-coding regions across cell lines. (F) 
Somatic mutant allele frequency of protein-coding genes in the CT26 tumor compared to the 
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CT26 cell line. Pearson correlation coefficient is also reported. (G) Somatic mutations and 
CNVs (determined using Seq2C from WES data) of 177 cancer or immune system-associated 
genes in the CT26 cell line and tumor. Gene aberrations that are not found in both the cell 
line and tumor are in the enlarged display. 
  
Figure 4: Transcriptomic analysis of in vivo tumors reveals predominance of immune 
pathways among differentially-expressed genes and reduced immune involvement in 
B16 tumors 
Transcriptomic analysis of murine syngeneic in vivo tumor samples showing (A) a clustergram 
of differentially-expressed gene-sets per model (FC +/- )'5ZKHUHWKHWRSWHQ
highest and lowest pathway Z scores (IPA comparison tool) per model were selected (sorted 
for non-disease canonical pathways). HCA (normalized, Ward linkage and Euclidean 
distance) for models only, with pathways ranked by absolute activation score (summed 
absolute Z score across all 15 lines). (B) Clustergram of murine syngeneic in vivo tumor 
samples based on differential expression of MHC class I and II pathway genes. HCA 
(normalized, Ward linkage and Euclidean distance) for models only, of normalized log2 gene 
expression intensity.  
 
Figure 5:   Differences in immune cell type-specific gene expression suggest marked 
heterogeneity in the tumor immune infiltrate between models 
Clustergram of murine syngeneic in vivo tumor samples based on differential expression of 
immune cell type-annotated genes from the Nanostring nCounter® PanCancer Immune 
Profiling Panel gene-list. HCA (normalized, Ward linkage and Euclidean distance) of 
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normalized log2 gene expression intensity with each column representing one individual 
mouse, n  4 replicates per tumor model. Clustered for samples, with genes ordered by mouse 
cell type annotation.  
 
Figure 6: Immune phenotyping reveals profound differences in the tumor micro-
environment across different syngeneic models 
Flow cytometric analysis of the tumor immune cell infiltrate in (A) 3 BALB/c models (CT26, 
RENCA and 4T1) and in (B) 3 C57BL/6 models (MC38, LL/2, and B16F10 AP-3) showing 
cell counts per mm3 of tumor for 9 immune cell types and their frequencies (as percentages of 
CD45+ cells). n PLFHSHUJURXSC: Percentages of NK cells that were positive for 
granzyme B in each model. D: Percentages of CD8+ T cells expressing Eomes, PD-1, Ki67 
and granzyme B in each model. *P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, 
7XNH\¶VPXOWLSOHFRPSDULVRQVWHVWE: Heatmap of the logged values for expression of 10 
cytokines in the lysates of 6 tumors. Data is representative of trends observed in at least 2 
independent experiments. 
 
Figure 7: Frequencies of immune cell types show much stronger variations between 
tumor types in the tumor infiltrate compared to the spleen and tumor-draining lymph 
nodes  
Flow cytometric analysis of the immune cell composition of (A and B) the spleen, (C and D) 
the tumor-draining lymph node (or inguinal lymph nodes in naïve mice) and (E and F) the 
tumor of mice bearing (A, C and E) 3 BALB/c models (CT26, RENCA and 4T1) or control 
naïve Balb/c mice and of mice bearing (B, D and F) 3 C57BL/6 models (MC38, LL/2, and 
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B16F10 AP-3) or control naïve C57BL/6 mice, showing frequencies of 9 immune cell types 
(as percentages of CD45+ cells). n PLFHSHUJURXSData is representative of trends 
observed in at least 2 independent experiments. 
 
 
 
